Tag: type 2 diabetes

Aflibercept Won’t Help Vision in Early Diabetic Retinopathy

Intravitreal injections with aflibercept (Eylea) don’t improve the visual acuity of people with nonproliferative diabetic retinopathy (NPDR), researchers say. The treatments do reduce the risk...

‘Couch Potato’ Lifestyles Cause Up to 8% of Global Deaths

TUESDAY, March 30, 2021 (HealthDay News) — “Couch potatoes,” take note: Sedentary behavior now accounts for up to 8% of non-communicable diseases and deaths worldwide,...

Contrary to Popular Belief, Insulin Can Be Stored Outside Fridge

Insulin may be more heat-stable during 28 days of use than current labeling suggests, a new study indicates. Instructions on insulin vials or pens indicate...

Obesity Helps Drive Half of New Diabetes Cases

“This requires policy-level changes, too,” Khan said, pointing to examples such as soda taxes and efforts to make fruits and vegetables more accessible in low-income...

Semaglutide for Weight Loss? A Good First STEP, With Caveats

The phase 3a STEP 1 trial that investigated the use of semaglutide (Novo Nordisk), a glucagon-like peptide-1 (GLP-1) agonist, for weight loss is aptly named,...

What’s the Best Second-Line Drug Class for Type 2 Diabetes?

Sodium-glucose cotransporter 2 (SGLT2) inhibitors to treat type 2 diabetes appear to confer greater cardiovascular benefit than glucagon-like peptide-1 (GLP-1) receptor agonists among older adults...

Metformin Could Help Prevent Some Breast Cancers

More study is needed to better understand whether there is a cause-effect relationship between metformin and cancer or whether the increased risk owes to an...

Cardiometabolic Subspecialty Is ‘One-Stop Shop’ Approach to Diabetes

A one-stop shop approach to managing the spectrum of complications in patients with type 2 diabetes with a coordinated, multidisciplinary team of clinicians has taken...

Further Warning on SGLT2 Inhibitor Use and DKA Risk in COVID-19

Use of sodium-glucose cotransporter 2 (SGLT2) inhibitors during acute COVID-19 illness raises the risk for euglycemic diabetic ketoacidosis (euDKA), a new case series suggests. Five...

FDA Welcomes Sotagliflozin Data for Heart Failure in Diabetes

The Food and Drug Administration has determined that data collected on the dual SGLT1/2 inhibitor sotagliflozin (Zynquista) for treating patients with type 2 diabetes in...

Endocrine Society Call for Action to Reduce Insulin Costs in US

The Endocrine Society has issued a new position statement calling on all stakeholders, including clinicians, to play a role in reducing the cost of insulin...

‘Keep Glucose in Check’ to Thwart Cardiac Autonomic Neuropathy

Among patients with type 2 diabetes at high risk of cardiovascular events, treating to tighter A1c and blood pressure targets was associated with a decreased...

Surgery Equals Drug Tx for Bleeding in Diabetic Retinopathy

In the treatment of vitreous hemorrhage from proliferative diabetic retinopathy, intraocular injection with anti–vascular endothelial growth factor (VEGF) shows similar efficacy to that of vitrectomy...

The Link Between Type 2 Diabetes and Heart Disease

Type 2 diabetes raises your odds of developing heart disease, as does prediabetes. If you’ve been diagnosed with either, start paying attention to your...

Twincretin Shows Positive Effects in Phase 3 Trial in Diabetes

Tirzepatide, a novel drug that acts via two related but separate pathways of glucose control, produced positive effects in top-line results from the phase 3,...

Peripheral Neuropathy Tied to Mortality in Adults Without Diabetes

Peripheral neuropathy is common in US adults and is associated with an increased risk of death, even in the absence of diabetes, researchers report today...

New CREDENCE Data Support SGLT2 Inhibitor Use in Advanced CKD

In a post-hoc analysis of the CREDENCE study, there were no safety signals when the sodium-glucose cotransporter 2 (SGLT2) inhibitor canagliflozin (Invokana, Janssen) was continued...

Ranibizumab Biosimilar Shows Equivalent Efficacy to Branded Drug for Neovascular AMD

NEW YORK (Reuters Health) – In a phase 3 study, the ranibizumab biosimilar SB11 demonstrated equivalent efficacy and similar safety and immunogenicity profiles compared with...

Age No Barrier to Weight Loss in Those With Morbid Obesity

Older adults should be recommended for hospital-based lifestyle interventions to reduce weight, say UK investigators after finding there was no difference in weight loss between...

New Study Pinpoints How Mediterranean Diet Reduces Diabetes Risk

The known reduction in the risk of type 2 diabetes associated with adoption of the Mediterranean diet appears specifically attributed to its beneficial effects on...

Mediterranean Diet Cuts Women’s Odds for Diabetes

By Steven Reinberg HealthDay Reporter TUESDAY, Nov. 24, 2020 (HealthDay News) — Overweight women who eat a Mediterranean-like diet may reduce their...

USPSTF Continues to Back Behavioral Intervention to Cut CVD Risk

Adults with risk factors for cardiovascular disease (CVD) should be offered or referred for behavioral counseling to promote a healthy diet and physical activity, the...

Metformin Improves Most Outcomes for T2D During Pregnancy

Women with type 2 diabetes who take metformin during pregnancy to control their blood glucose levels experience a range of benefits, including reduced weight gain,...

Empagliflozin Favorably Reshaped LVs in HFrEF Patients

Treatment with the SGLT2 inhibitor empagliflozin led to significant reductions in both left ventricular end systolic and diastolic volumes in two independent randomized studies of...

Omega-3, Vit-D Both Fail at AF Primary Prevention in VITAL-Rhythm

Clinical trials of omega-3 fatty acid or vitamin D supplements have followed a long and winding road in search of benefits in cardiovascular (CV) disease,...